Hematopoietic stem cell transplantation and adoptive cell therapies

Cimeio Therapeutics is pioneering a novel approach to immunotherapy specifically designed for hematologic disorders. Their innovative platform focuses on the development of Shielded-Cell & Immunotherapy Pairs™ (SCIP), which combines immunotherapies with modified variants of naturally occurring cell surface proteins in hematopoietic stem cells (HSCs). This technology allows for the selective targeting and depletion of diseased cells while simultaneously protecting healthy cells from the effects of the immunotherapy. By employing gene editing techniques, Cimeio can create epitope-edited variants of these proteins that retain their functionality but are resistant to depletion by the paired immunotherapy, thereby enhancing the safety and efficacy of treatment.

The company’s research has demonstrated the potential of their therapies to provide curative solutions for challenging conditions such as blood cancers, autoimmune disorders, and genetic diseases. Their recent publications, including findings in prestigious journals like Nature, highlight the effectiveness of their CD45 antibody-drug conjugate (ADC) and CD52 shielding variant, which together represent a promising universal therapy for blood cancers. Cimeio's commitment to advancing these groundbreaking therapies positions them at the forefront of immunotherapy innovation, aiming to address the limitations of existing treatments and improve patient outcomes in hematologic malignancies.

Switzerland

Cimeio Therapeutics is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs for patients with serious and life-threatening diseases. Cimeio’s proprietary technology platform is based on the discovery of protein variants, which when edited into cells allow them to maintain full function while resisting paired immunotherapy depletion. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders.

Cimeio Therapeutics

Company Details